{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:26:54Z","timestamp":1789712814601,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1741-7015-11-234","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T10:46:59Z","timestamp":1383562019000},"source":"Crossref","is-referenced-by-count":34,"title":["Managing HIV\/hepatitis C co-infection in the era of direct acting antivirals"],"prefix":"10.1186","volume":"11","author":[{"given":"J\u00fcrgen K","family":"Rockstroh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Bhagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"key":"868_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1468-1293.2012.01051.x","volume":"14","author":"R Weber","year":"2013","unstructured":"Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, Cavassini M, Calmy A, Bernasconi E, Schmid P, Flepp M, Kowalska J, Ledergerber B, Swiss HIV Cohort Study (SHCS): Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013, 14: 195-207. 10.1111\/j.1468-1293.2012.01051.x.","journal-title":"HIV Med"},{"key":"868_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1086\/432762","volume":"192","author":"JK Rockstroh","year":"2005","unstructured":"Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J, EuroSIDA Study Group: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005, 192: 992-1002. 10.1086\/432762.","journal-title":"J Infect Dis"},{"key":"868_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1086\/592171","volume":"198","author":"V Soriano","year":"2008","unstructured":"Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J, EuroSIDA Study Group: Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008, 198: 1337-1344. 10.1086\/592171.","journal-title":"J Infect Dis"},{"key":"868_CR4","first-page":"2563","volume":"91","author":"JK Rockstroh","year":"1996","unstructured":"Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, Fischer HP, Oldenburg J, Brackmann HH, Sauerbruch T: Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol. 1996, 91: 2563-2568.","journal-title":"Am J Gastroenterol"},{"key":"868_CR5","doi-asserted-by":"publisher","first-page":"i47","DOI":"10.1136\/gutjnl-2012-302062","volume":"61","author":"K Lacombe","year":"2012","unstructured":"Lacombe K, Rockstroh J: HIV and viral hepatitis co-infections: advances and challenges. Gut. 2012, 61: i47-i58. 10.1136\/gutjnl-2012-302062.","journal-title":"Gut"},{"key":"868_CR6","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","volume":"362","author":"N Qurishi","year":"2003","unstructured":"Qurishi N, Kreuzberg C, L\u00fcchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus co-infection. Lancet. 2003, 362: 1708-1713. 10.1016\/S0140-6736(03)14844-1.","journal-title":"Lancet"},{"key":"868_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa040842","volume":"351","author":"FJ Torriani","year":"2004","unstructured":"Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garc\u00eda J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group: Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004, 351: 438-450. 10.1056\/NEJMoa040842.","journal-title":"N Engl J Med"},{"key":"868_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1089\/aid.2007.0011","volume":"23","author":"M N\u00fa\u00f1ez","year":"2007","unstructured":"N\u00fa\u00f1ez M, Miralles C, Berd\u00fan MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de Los Santos I, San Joaqu\u00edn I, Echeverr\u00eda S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, Garc\u00eda-Samaniego J, Soriano V, PRESCO Study Group: Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007, 23: 972-982. 10.1089\/aid.2007.0011.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"868_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1310\/hct1303-142","volume":"13","author":"M Rodriguez-Torres","year":"2012","unstructured":"Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, Serr\u00e3o R, Sola R, Bertasso A, Passe And S, Stancic S: Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials. 2012, 13: 142-152. 10.1310\/hct1303-142.","journal-title":"HIV Clin Trials"},{"key":"868_CR10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","volume":"159","author":"MS Sulkowski","year":"2013","unstructured":"Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V: Combination therapy with telaprevir for chronic hepatitis C Virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013, 159: 86-96.","journal-title":"Ann Intern Med"},{"key":"868_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","volume":"13","author":"M Sulkowski","year":"2013","unstructured":"Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W, P05411 study investigators: Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013, 13: 597-605. 10.1016\/S1473-3099(13)70149-X.","journal-title":"Lancet Infect Dis"},{"key":"868_CR12","volume-title":"20th Conference on Retroviruses and Opportunistic Infections, Atlanta","author":"L Cotte","year":"2013","unstructured":"Cotte L, Braun J, Lascoux-Combe C, Vincent C, Pol S, Valentin M-A, Lacombe K, Nau D, Aboulker JP, Molina J-M, ANRS HC26 Study Group: High early virological response with telaprevir-pegylated-interferon-ribavirin in treatment-experienced hepatitis C virus genotype 1\/HIV co-infected patients: ANRS HC26 TelapreVIH Study. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta. 2013, abstract 36"},{"key":"868_CR13","volume-title":"20th Conference on Retroviruses and Opportunistic Infections, Atlanta","author":"I Poizot-Martin","year":"2013","unstructured":"Poizot-Martin I, Bellissant E, Piroth L, Renault A, Quertainmont Y, Rosenthal E, Alric L, Guyader D, Bourliere M, Molina J-M, ANRS-HC27 BOCEPREVIH Study Group: ANRS-HC27 BocepreVIH interim analysis: high early virologic response with boceprevir\u2009+\u2009pegylated interferon\u2009+\u2009ribivirin in hepatitis C Virus\/HIV co-infected patients with previous failure to pegylated interferon\u2009+\u2009ribivirin. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta. 2013, abstract 37"},{"key":"868_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/2047-783X-14-12-507","volume":"14","author":"M Vogel","year":"2009","unstructured":"Vogel M, Rockstroh JK: The treatment of chronic hepatitis C virus infection in HIV co-infection. Eur J Med Res. 2009, 14: 507-515. 10.1186\/2047-783X-14-12-507.","journal-title":"Eur J Med Res"},{"key":"868_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/hiv.12068","volume":"14","author":"D Grint","year":"2013","unstructured":"Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren J, Rockstroh J, Kirk O, Mocroft A, EuroSIDA in EuroCoord: Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med. 2013, 14: 614-623.","journal-title":"HIV Med"},{"key":"868_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","volume":"9","author":"LI Backus","year":"2011","unstructured":"Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA: A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011, 9: 509-516. 10.1016\/j.cgh.2011.03.004.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"868_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/hep.23020","volume":"50","author":"J Berenguer","year":"2009","unstructured":"Berenguer J, Alvarez-Pellicer J, Mart\u00edn PM, L\u00f3pez-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bell\u00f3n JM, Gonz\u00e1lez-Garc\u00eda J, GESIDA3603\/5607 Study Group: Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009, 50: 407-413. 10.1002\/hep.23020.","journal-title":"Hepatology"},{"key":"868_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/cid\/cis500","volume":"55","author":"J Berenguer","year":"2012","unstructured":"Berenguer J, Rodr\u00edguez E, Miralles P, Von Wichmann MA, L\u00f3pez-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, T\u00e9llez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bell\u00f3n JM, Gonz\u00e1lez-Garc\u00eda J, GESIDA HIV\/HCV Cohort Study Group: Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2012, 55: 728-736. 10.1093\/cid\/cis500.","journal-title":"Clin Infect Dis"},{"key":"868_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jhep.2013.01.042","volume":"58","author":"J Berenguer","year":"2013","unstructured":"Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, L\u00f3pez-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, T\u00e9llez MJ, Quereda C, Tural C, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Barquilla E, Bell\u00f3n JM, Gonz\u00e1lez-Garc\u00eda J, GESIDA HIV\/HCV Cohort Study Group: Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013, 58: 1104-1112. 10.1016\/j.jhep.2013.01.042.","journal-title":"J Hepatol"},{"key":"868_CR20","first-page":"321","volume":"369","author":"JM Pawlotsky","year":"2013","unstructured":"Pawlotsky JM: Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol. 2013, 369: 321-342.","journal-title":"Curr Top Microbiol Immunol"},{"key":"868_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","volume":"59","author":"C H\u00e9zode","year":"2013","unstructured":"H\u00e9zode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourli\u00e8re M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, M\u00e9tivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, et al: Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013, 59: 434-441. 10.1016\/j.jhep.2013.04.035.","journal-title":"J Hepatol"},{"key":"868_CR22","volume-title":"20th Conference on Retroviruses and Opportunistic Infections, Atlanta","author":"D Dieterich","year":"2013","unstructured":"Dieterich D, Soriano V, Nelson M, Rockstroh J, Arasteh K, Bhagani S, Talal A, Tural C, Vinisko R, Kort J: STARTVerso 4: high rates of early virologic response in hepatitis C Virus genotype 1\/HIV co-infected patients treated with faldaprevir\u2009+\u2009pegylated interferon and ribavirin. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta. 2013, abstract 40LB"},{"key":"868_CR23","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/hep.26276","volume":"57","author":"MS Sulkowski","year":"2013","unstructured":"Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, B\u00f6cher WO: Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-na\u00efve patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology. 2013, 57: 2143-2154. 10.1002\/hep.26276.","journal-title":"Hepatology"},{"key":"868_CR24","volume-title":"20th Conference on Retroviruses and Opportunistic Infections, Atlanta","author":"D Dieterich","year":"2013","unstructured":"Dieterich D, Rockstroh J, Orkin C, Gutierrez F, Klein M, Reynes J, Jessner W, Lenz O, Peeters M, Beumont-Mauviel M: Simeprevir with pegylated interferon\/ribavirin in patients co-infected with chronic hepatitis C virus and HIV-1: week-24 interim analysis of the TMC435-C212 study. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta. 2013, abstract 154LB"},{"key":"868_CR25","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/j.1478-3231.2012.02796.x","volume":"32","author":"P Ingiliz","year":"2012","unstructured":"Ingiliz P, Rockstroh JK: HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int. 2012, 32: 1194-1199. 10.1111\/j.1478-3231.2012.02796.x.","journal-title":"Liver Int"},{"key":"868_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/QAI.0b013e31815ac47d","volume":"47","author":"M Opravil","year":"2008","unstructured":"Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, Torriani FJ, Depamphilis J, Dieterich DT: Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV\/hepatitis C virus coinfection. J Acquir Immune Defic Syndr. 2008, 47: 36-49. 10.1097\/QAI.0b013e31815ac47d.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"868_CR27","volume-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012). San Francisco","author":"M Rodriguez-Torres","year":"2012","unstructured":"Rodriguez-Torres M, Gonzalez M, Rossi S, et al: HIV\/HCV coinfected and HCV monoinfected patients have similar early HCV viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir (SOF). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012). San Francisco. 2012, Abstract H1921a"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-11-234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-11-234\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-11-234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T19:29:09Z","timestamp":1746041349000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-11-234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["868"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-11-234","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,1]]},"article-number":"234"}}